Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 14/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410942 | 0.91 | HTR3A (0.55) | HTR3ACNR2CNR1 | |
| SCHEMBL5448828 | 0.87 | HTR3A (0.52) | HTR3AATMCNR2CNR1 | |
| SCHEMBL14411366 | 0.86 | HTR3A (0.53) | HTR3AATMIDO1 | |
| SCHEMBL14463900 | 0.84 | ATM (0.43) | HTR3AATMIDO1CNR2CNR1 | |
| SCHEMBL16316890 | 0.80 | HTR3A (0.49) | HTR3ACNR2CNR1 | |
| SCHEMBL5441614 | 0.79 | ATM (0.48) | HTR3AATMCNR2CNR1 | |
| SCHEMBL5452918 | 0.79 | HTR3A (0.49) | HTR3AIDO1CNR2 | |
| SCHEMBL16316982 | 0.78 | HTR3A (0.47) | HTR3AATMIDO1 | |
| SCHEMBL5441702 | 0.77 | HTR3A (0.44) | HTR3AATMCNR2CNR1 | |
| SCHEMBL5444494 | 0.77 | HTR3A (0.44) | HTR3AATMCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HTR3A 373/4885ATM 4514/4885IDO1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.